Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind study of mefunidone hydrochloride tablets in type 2 diabetic kidney disease
CTR20230987Phase 2Active
- Sponsor
- Nanxin Pharmaceutical
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of meflunidone hydrochloride in diabetic glomerulosclerosis, sponsored by Nanxin Pharmaceutical. Started Jul 2023; status: active.
02
Drugs
meflunidone hydrochloride
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on CTR20230987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230987.